Matches in Wikidata for { <http://www.wikidata.org/entity/Q57116327> ?p ?o ?g. }
Showing items 1 to 64 of
64
with 100 items per page.
- Q57116327 description "article scientifique publié en 2017" @default.
- Q57116327 description "article" @default.
- Q57116327 description "im September 2017 veröffentlichter wissenschaftlicher Artikel" @default.
- Q57116327 description "wetenschappelijk artikel" @default.
- Q57116327 description "наукова стаття, опублікована у вересні 2017" @default.
- Q57116327 name "Randomized Phase III Trial of Trastuzumab Plus Capecitabine With or Without Pertuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Who Experienced Disease Progression During or After Trastuzumab-Based T" @default.
- Q57116327 name "Randomized Phase III Trial of Trastuzumab Plus Capecitabine With or Without Pertuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Who Experienced Disease Progression During or After Trastuzumab-Based T" @default.
- Q57116327 type Item @default.
- Q57116327 label "Randomized Phase III Trial of Trastuzumab Plus Capecitabine With or Without Pertuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Who Experienced Disease Progression During or After Trastuzumab-Based T" @default.
- Q57116327 label "Randomized Phase III Trial of Trastuzumab Plus Capecitabine With or Without Pertuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Who Experienced Disease Progression During or After Trastuzumab-Based T" @default.
- Q57116327 prefLabel "Randomized Phase III Trial of Trastuzumab Plus Capecitabine With or Without Pertuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Who Experienced Disease Progression During or After Trastuzumab-Based T" @default.
- Q57116327 prefLabel "Randomized Phase III Trial of Trastuzumab Plus Capecitabine With or Without Pertuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Who Experienced Disease Progression During or After Trastuzumab-Based T" @default.
- Q57116327 P1433 Q57116327-6BE532D0-C2BE-475A-99CC-E72DE5A29EF1 @default.
- Q57116327 P1476 Q57116327-C7A03325-DF06-4CFB-9151-A87C2241809B @default.
- Q57116327 P2093 Q57116327-53C7BE95-FE1E-4BAF-9BA8-982BDEFE8E6E @default.
- Q57116327 P2093 Q57116327-5B686B36-9DB7-4912-B2DD-FA2E855174DE @default.
- Q57116327 P2093 Q57116327-67D79CE8-2248-484E-920D-C23DC28BFC62 @default.
- Q57116327 P2093 Q57116327-826DD3B7-6BAF-4A54-B0E1-80A8B9D1B9DA @default.
- Q57116327 P2093 Q57116327-B7B3C527-2479-4DEC-8961-D3B7E55C6524 @default.
- Q57116327 P2093 Q57116327-B9A5C214-D5D4-4E1F-8F07-A867E7919D5A @default.
- Q57116327 P2093 Q57116327-D215C31C-D4BE-4E14-9A73-0E243D5B7C95 @default.
- Q57116327 P2093 Q57116327-E83BB0FD-F39C-4804-A9F5-76AAEC4CA389 @default.
- Q57116327 P2093 Q57116327-F19509A1-9D16-41B3-A0D4-74CA657802D4 @default.
- Q57116327 P304 Q57116327-60FFFFEA-E961-42FC-88C6-CE13A0DD0A19 @default.
- Q57116327 P31 Q57116327-A324E2BF-D94A-47E9-87DF-BE28D6C796CA @default.
- Q57116327 P356 Q57116327-D434E537-19D8-43C8-A921-9EC9C2F3F50F @default.
- Q57116327 P407 Q57116327-C74495C6-93A6-462A-BC9A-CC32AEE5F9E2 @default.
- Q57116327 P433 Q57116327-C940F278-B157-4159-834C-F8DB89257D81 @default.
- Q57116327 P478 Q57116327-2153C848-B726-44AB-94E7-E2EDFCA170DA @default.
- Q57116327 P50 Q57116327-25FDAD75-857A-46BF-BF7D-263DB8443A9F @default.
- Q57116327 P50 Q57116327-E38D32C5-48C9-4535-A847-0ABD757A0ADB @default.
- Q57116327 P577 Q57116327-744BE1CD-1F50-4487-9757-AB72BD124689 @default.
- Q57116327 P698 Q57116327-F7707AFB-E320-4BAB-B282-3C5D217129CA @default.
- Q57116327 P921 Q57116327-4D0923BA-869A-4484-93EA-C139D5947ADA @default.
- Q57116327 P921 Q57116327-ADC2A453-46F3-46BF-9E59-7CCA21CBA23B @default.
- Q57116327 P921 Q57116327-E0CD3F9B-3440-47C6-8BF9-B70B8CA22C27 @default.
- Q57116327 P921 Q57116327-FAE25534-165F-4E98-920E-FEE4111EE75E @default.
- Q57116327 P356 JCO.2016.70.6267 @default.
- Q57116327 P698 28437161 @default.
- Q57116327 P1433 Q400292 @default.
- Q57116327 P1476 "Randomized Phase III Trial of Trastuzumab Plus Capecitabine With or Without Pertuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Who Experienced Disease Progression During or After Trastuzumab-Based Therapy" @default.
- Q57116327 P2093 "Antonio Carlos Sánchez Ruiz" @default.
- Q57116327 P2093 "Gianluca Tomasello" @default.
- Q57116327 P2093 "Hannah Douthwaite" @default.
- Q57116327 P2093 "István Láng" @default.
- Q57116327 P2093 "Jennifer Eng-Wong" @default.
- Q57116327 P2093 "Mohammed Rizwanullah" @default.
- Q57116327 P2093 "Montserrat Muñoz" @default.
- Q57116327 P2093 "Sarah Heeson" @default.
- Q57116327 P2093 "Tanja Badovinac Crnjevic" @default.
- Q57116327 P304 "3030-3038" @default.
- Q57116327 P31 Q13442814 @default.
- Q57116327 P356 "10.1200/JCO.2016.70.6267" @default.
- Q57116327 P407 Q1860 @default.
- Q57116327 P433 "26" @default.
- Q57116327 P478 "35" @default.
- Q57116327 P50 Q39953827 @default.
- Q57116327 P50 Q58821370 @default.
- Q57116327 P577 "2017-04-24T00:00:00Z" @default.
- Q57116327 P698 "28437161" @default.
- Q57116327 P921 Q12859063 @default.
- Q57116327 P921 Q412616 @default.
- Q57116327 P921 Q420207 @default.
- Q57116327 P921 Q42824827 @default.